HotSpot Therapeutics scores $45 mln Series A
Cambridge, Massachusetts-based HotSpot Therapeutics, a new biotechnology company targeting nature's regulatory hotspots to discover and develop medicines, has raised $45 million in Series A financing. HotSpot's investors include Atlas Venture and Sofinnova Partners.
17 July 2018•1 min read
